• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

    10/18/24 12:50:54 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZNTL alert in real time by email
    SC 13G/A 1 Zentalis_Pharma_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    ZENTALIS PHARMACEUTICALS INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    98943L107

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    98943L107 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,155,274

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,246,613

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,246,613.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.8%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    98943L107 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      ZENTALIS PHARMACEUTICALS INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      530 7TH AVENUE SUITE 2201 NEW YORK NY 10018 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      98943L107

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    98943L107 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 1,246,613.00  
      (b) Percent of class: 1.8%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 1,155,274
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 1,246,613
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ý
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    98943L107 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $ZNTL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZNTL

    DatePrice TargetRatingAnalyst
    8/12/2024$4.00Underperform → Neutral
    Wedbush
    6/20/2024$28.00 → $5.00Buy → Neutral
    UBS
    6/18/2024$42.00 → $6.00Buy → Hold
    Jefferies
    6/18/2024$38.00 → $8.00Overweight → Equal-Weight
    Morgan Stanley
    6/18/2024$15.00 → $4.00Neutral → Underperform
    Wedbush
    6/18/2024Overweight → Equal Weight
    Wells Fargo
    11/8/2023$38.00 → $12.00Outperform → Neutral
    Wedbush
    11/7/2023$15.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $ZNTL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

      First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, announced financial results for the first quarter 2025 and highlighted recent oper

      5/14/25 4:05:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on May 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company's common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual's entering

      5/1/25 5:00:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

      Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). As previously d

      4/28/25 8:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    SEC Filings

    See more
    • Zentalis Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)

      5/20/25 6:01:40 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Zentalis Pharmaceuticals Inc.

      S-8 - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)

      5/14/25 4:15:53 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Zentalis Pharmaceuticals Inc.

      10-Q - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)

      5/14/25 4:13:06 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Financials

    Live finance-specific insights

    See more
    • Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

      Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy cohorts in key clinical studies, well-characterized safety and tolerability profile shows no new safety signals Company aligned with FDA on seamless study design for DENALI Part 2 in patients with Cyclin E1+ PROC; study expected to begin 1H 2025 Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Management to host conference call today at 8:00 am ET SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (

      1/29/25 7:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

      FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the

      6/18/24 7:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing

       ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability with no treatment-related discontinuations Company plans to update efficacy data from Phase 1 monotherapy dose optimization study and provide program timeline updates for three azenosertib Phase 2 monotherapy trials currently enrolling patients at the RP2D in the second half of 2023 Investor call at 8:00 a.m. ET today to review azenosertib monotherapy data supporting dose selection and chemotherapy combination da

      6/6/23 6:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Myers Scott Dunseth bought $29,373 worth of shares (21,000 units at $1.40), increasing direct ownership by 8% to 281,192 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      4/30/25 5:07:20 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/12/25 5:00:31 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Skvarka Jan bought $103,446 worth of shares (60,000 units at $1.72), increasing direct ownership by 67% to 149,551 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/4/25 4:45:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

      SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)

      11/14/24 4:20:13 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

      SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)

      11/12/24 6:00:27 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zentalis Pharmaceuticals Inc.

      SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)

      11/6/24 2:47:51 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Myers Scott Dunseth bought $29,373 worth of shares (21,000 units at $1.40), increasing direct ownership by 8% to 281,192 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      4/30/25 5:07:20 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/12/25 5:00:31 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PAO and Interim PFO Vultaggio Vincent was granted 158,586 shares and sold $4,476 worth of shares (2,615 units at $1.71), increasing direct ownership by 461% to 189,826 units (SEC Form 4)

      4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

      2/5/25 6:33:02 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zentalis Pharma upgraded by Wedbush with a new price target

      Wedbush upgraded Zentalis Pharma from Underperform to Neutral and set a new price target of $4.00

      8/12/24 8:08:44 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharma downgraded by UBS with a new price target

      UBS downgraded Zentalis Pharma from Buy to Neutral and set a new price target of $5.00 from $28.00 previously

      6/20/24 7:40:40 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharma downgraded by Jefferies with a new price target

      Jefferies downgraded Zentalis Pharma from Buy to Hold and set a new price target of $6.00 from $42.00 previously

      6/18/24 2:21:55 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZNTL
    Leadership Updates

    Live Leadership Updates

    See more
    • Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

      Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year end 2026 Strengthened management team to support execution of highly focused strategy $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027 SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and othe

      3/26/25 4:05:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

      Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2 Planned workforce reduction of approximately 40% of employees Corporate event to be held on January 29, 2025 at 8:00am ET to provide key updates on azenosertib clinical data, development and regulatory path SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced a restructuring of its business operations and research and development organ

      1/28/25 4:05:00 PM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zentalis Pharmaceuticals Announces Key Management Appointments

      SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer. "Zentalis is sharply focused on our goal of bringing azenosertib to patients with gynecological malignancies," said Julie Eastland, Chief Executive Officer. "To support this goal, we are continuing to tune our leadership team and today announced the appointment of two talented leaders with a strong track record o

      12/12/24 7:00:00 AM ET
      $ZNTL
      Biotechnology: Pharmaceutical Preparations
      Health Care